The Lancet Oncology
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
By Wyndham Hopkins Wilson, Owen A. O’Connor, Myron Stefan Czuczman, Show 13 more authorsRod A. Humerickhouse
Non-randomised trial in 55 peopleInterventions
Multicentre, registered NCT00406809
The paper
National Institutes of Health; Abbott (United States)
The Lancet Oncology, 18 Nov 2010
